CP3R and AH’s Performance for Non-Small Cell Lung Cancer
SURGERY IS NOT FIRST COURSE OF TREATMENT FOR NON-SMALL CELL LUNG CANCER THAT HAS NOT SPREAD TO DISTANT ORGANS OR AREAS
Surgery is not First Course of Treatment for Non-Small Cell Lung Cancer That Has Not Spread to Distant Organs or Areas
This quality measure examines whether surgery was used within the ﬁrst course of treatment for Non-Small Cell Lung Cancer that has not spread to other organs. Abington Hospital is in compliance at 100% compared to CoC average of 90.9%.
CHEMOTHERAPY IN LYMPH NODE POSITIVE NON-SMALL CELL LUNG CANCER
Chemotherapy in Lymph Node Positive Non-Small Cell Lung Cancer
Chemotherapy administered within four months to day preoperatively or day of surgery to six months postoperatively, or it is considered for surgically resected cases with pathologic, lymph node positive Non-Small Cell Lung Cancer. Abington Hospital’s compliance is 100% compared to the CoC average of 90.7%.